Journals / Fırat Tıp Dergisi / 2012 / Cilt: 17 - Sayı: 1

Serum adiponectin levels in acute ıschemic stroke and ıt’s probable role on ıschemic stroke

Akut iskemik inmede serum adiponektin düzeyi ve iskemik inme oluşumunda muhtemel rolü

Pages
28–31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results suggest that serum adiponectin levels in the patients with acute ischemic stroke do not show a statistically significant difference when compared to healthy controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate serum levels of adiponectin in the different groups of patients with ischemic stroke and healthy control subjects.
📊
Key Findings & Data:Material and Methods: 50 patients with acute ischemic stroke and 30 healthy controls were included in this study.
💡
Conclusion & Impact:Conclusion: These results suggest that serum adiponectin levels in the patients with acute ischemic stroke do not show a statistically significant difference when compared to healthy controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to evaluate serum levels of adiponectin in the different groups of patients with ischemic stroke and healthy control subjects. Material and Methods: 50 patients with acute ischemic stroke and 30 healthy controls were included in this study. Serum levels of adiponectin were compared with respect to the diabetics and nondiabetics and also were compared according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria in the patients with stroke. Results: Serum adiponectin levels were not significantly different between the stroke patients and healthy groups and also between the stroke subgroups (p>0.05). There was no significant difference between diabetic and non-diabetic stroke patients (p>0.05). Conclusion: These results suggest that serum adiponectin levels in the patients with acute ischemic stroke do not show a statistically significant difference when compared to healthy controls. We conclude from our data that serum adiponectin levels have no important effect on the ischemic stroke.

Özet

Amaç: Bu çalışmada amacımız iskemik inmeli hastaların farklı gruplarında ve sağlıklı bireylerde serum adiponektin düzeylerini karşılaştırmaktır. Gereç ve Yöntemler: Çalışmaya akut iskemik inmeli 50 hasta ve sağlıklı 30 gönüllü birey alındı. Adiponektin düzeyleri inmeli hastalarda diabetik ve non-diabetik olmalarına göre ve TOAST (Trial of Org 10172 in Acute Stroke Treatment) kriterlerine göre alt gruplara ayrıldıktan sonra karşılaştırıldı. Bulgular: İnmeli hasta grubuyla kontrol grubunun serum adiponektin düzeyleri arasında ve ayrıca hasta grubunu oluşturan alt grupların serum adiponektin düzeyleri arasında anlamlı farklılık yoktu (p>0.05). Yine inmeli hasta grubunda diabetik ve non-diabetik hastalarda adiponektin düzeyleri arasında anlamlı farklılık yoktu (p>0.05). Sonuç: Bu çalışma sonuçları adiponektinin akut iskemik inmeli hastalarda ki serum düzeylerinin normal kontrollere göre farklı olmadığını gösterdi. Bu verilere göre iskemik inme de adiponektin molekülünün etkili bir rol almadığını düşünüyoruz.

🔖

Cite This Article

BERİLGEN, M. S., ERDOĞAN, E., ÖZDEMİR, H. H., KAPAN, O., DEMİR, C. F. (2012). Serum adiponectin levels in acute ıschemic stroke and ıt’s probable role on ıschemic stroke. Fırat Tıp Dergisi, Cilt: 17 - Sayı: 1, 28–31. https://ajindex.com/articles/216848

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wolfe CDA. The impact of stroke. Br Med Bull, 2000; 56: 275-286
  2. Hatano S. Experience from a multicenter stroke register: a preliminary report. Bulletin of the World Health Organization, 1999; 54: 541-553
  3. Hankey GJ. Stroke: How large a public health problem, and how can the neurologist help? Arch Neurol 1999; 56: 748-754
  4. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assement. Circulation 2004; 109: 15-19
  5. Arner P. Not all fat is a like. Lancet 1998; 351: 1301-1302
  6. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450
  7. Friedman JM. Obesity in the new millennium. Nature 2000; 404: 632-634
  8. Maeda K, Okubo K, Shimomura I, et al. Cdna cloning and expression of a novel aipose-spesific collagen-like factor, apM1 (adipose most abundant gen transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289
  9. Ouchi N, Kihara S, Arita Y, et al. Modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponektin. Circulation 1999; 100: 2473-2476
  10. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial Nf-Kb signaling through a C-Amp dependent pathway. Circulation 2000; 102: 1296-1301
  11. Palomer X, Perez A, Blanco-Vaca F. Adiponectin: A new link between obesity, insulin resistance and cardiovascular disease. Medicina Clinica 2005; 124: 388-395
  12. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491
  13. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein-E deficient mice. Circilation 2002; 106: 2767-2770
  14. Hotta K, Funahashi T, Arita Y, et al. Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599
  15. Matsumato M, Ishikawa S, Kajii E. Association of adiponectin with cerebrovascular disease. Stroke 2008; 39: 323-328
  16. Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 821
  17. Yamamoto Y, Hrose H, Saito I, et al. Corelation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholestrol ind